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ABSTRACT The postgenomic era is providing a wealth of information about the genes involved in many cellular processes.
However, the ability to apply this information to understanding cellular signal transduction is limited by the lack of tools that
quantitatively describe cellular signaling processes. The objective of the current studies is to provide a framework for modeling
cellular signaling processes beginning at a plasma membrane receptor and ending with a measurable endpoint in the signaling
process. Agonist-induced Ca21 mobilization coupled to down stream phosphorylation events was modeled using knowledge of
in vitro and in vivo process parameters. The simulation process includes several modules that describe cellular processes
involving receptor activation phosphoinositide metabolism, Ca21-release, and activation of a calmodulin-dependent protein
kinase. A Virtual Cell-based simulation was formulated using available literature data and compared to new and existing
experimental results. The model provides a new approach to facilitate hypothesis-driven investigation and experimental design
based upon simulation results. These investigations may be directed at the timing of multiple phosphorylation/
dephosphorylation events affecting key enzymatic activities in the signaling pathway.
INTRODUCTION
Regulation of cell function involves the simultaneous opera-
tion of multiple signaling pathways that translate signals
(extracellular and intracellular) into cellular responses. In
the postgenomic era, components of signal transduction
pathways are being elucidated by genomic and proteomics
methods. Although this information allows the creation of
testable pathway maps, the details of the signal transduction
pathway (kinetics, feedback, and concentration dependen-
cies) are poorly understood because there are many variables
and conditions that need to be integrated (Slepchenko et al.,
2002; Bray, 1997). How the cellular biochemistry is coordi-
nated to deﬁne a process operation remains a large problem.
Another complication is that different cell types may have
common signal transduction pathways, but the details leading
to the endpoints of these pathsmay be different. Therefore, we
should expect that parameters controlling a cellular signaling
process are ﬁne-tuned to speciﬁc functional requirements.
Without quantitative models, the methods to obtain these
parameters are limited. Traditionally, a logical guess is made
as to the importance of a component and by pharmacological
intervention or genetic manipulation, the component is per-
turbed and the resulting effects on the system observed. The
problem is that this one-at-a-time approach is time-consuming
and usually not quantitative. Biological systems analysis
through computer simulation offers one way to integrate pro-
posed models or signal transduction maps, and empirical data
to formulate complex systems so that ‘‘what if’’ questions
may be asked ahead of experimental execution.Mathematical
formulations and computer programs that simulate signaling
ﬂuxes, enzyme kinetics, and metabolism have been described
and validated. Thus, the task at hand is to take advantage of
these tools to construct quantitative simulation models that
will allow the testing of hypotheses that arise from observa-
tions of cellular pathology or effects of various external
stimuli on gene expression and cellular function.
In the current effort, the Virtual Cell simulation and
analysis suite was used to develop a complete agonist-
initiated signaling and biological response system. Using
existing Virtual Cell models that include phospholipid (Xu
et al., 2003) and Ca21 mobilization modules (Fink et al.,
1999, 2000), new modules for modeling the upstream events
that trigger agonist-induced Ca21mobilization were coupled
to downstream events of Ca21 signaling and measurable
endpoints. A generic Ca21 signaling model based upon
existing G-protein-coupled receptor (GPCR) models for the
purine receptor (Lemon et al., 2003a,b) and chemokine
receptors (Riccobene et al., 1999; Adams et al., 1998; Shea
and Linderman, 1997) was developed. Models were reﬁned
using existing experimental dose/response data obtained with
various ligands. (Monck et al., 1988; Moneer and Taylor,
2002; Marsh and Hill, 1993; Leeb-Lundberg et al., 2001;
Schaeffer et al., 2001). Thus, this new model is applicable to
a variety of Ca21-mobilizing agonists by using receptor-
speciﬁc parameters that are obtainable from existing literature
or from readily designed experiments. The ligand-receptor
activation model and parameters for processes that generate
second messengers (inositol tris 1,4,5 -phosphate (IP3) and
Ca21) were then coupled to a prototypical downstream
process: Ca21-mediated initiation of smooth muscle contrac-
tion via the phosphorylation of myosin II. Extensive
experimental work has been done on the myosin-mediated
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process in various cell types and many of the components
and parameters needed for modeling have been reported.
However, what is needed is the formulation of an in silico
simulation that includes a continuous path of coupled com-
ponents. Although the network of interconnected signaling
pathways is complex, the current results demonstrate that
appropriately selected parameters allow successful modeling
of a prototypical Ca21 signal transduction process. Addition-
ally, scientiﬁc insights can be realized by executing the
simulation process leading to new hypotheses that can be
tested experimentally.
METHODS
Model strategy and construction
A schematic of the agonist-induced Ca21 signaling process is illustrated in
Fig. 1. The prototype is a smooth muscle cell that includes GPCRs for
agonists such as bradykinin, angiotensin II, etc. The primary events leading
to Ca21 mobilization by such agonists are mediated by the activation of
phospholipase C (PLC) that hydrolyzes the lipid, phosphatidylinositol 4,5
phosphate (PIP2) to generate IP3. IP3 then diffuses through the cell to the
endoplasmic reticulum (ER) and binds to the IP3-receptor channel that
releases Ca21 from the ER. In the current model the downstream event
involves the Ca21 effector calmodulin (CaM), its binding to myosin light
chain kinase (MLCK), activation of the CaM:MLCK complex, and
phosphorylation of the regulatory myosin light chain (MLC) that initiates
contraction in smooth muscle and motility in nonmuscle cells. Also included
are several control elements that are involved in regulating the level and
duration of MLC phosphorylation. These control elements include
regulation of MLCK by other protein kinases, the dephosphorylation of
myosin light chains by MLC phosphatase (MLCP), and both up- and down-
regulation of this phosphatase activity. These elements are necessarily
complex and not completely understood, because several protein kinases and
signaling networks are involved in regulating MLC phosphatase activity.
However, the advantage of using a simulation environment is that control
elements can be modiﬁed as needed. It is envisioned that other Ca21-
mediated downstream processes such as secretion and gene transcription can
be modeled in a similar fashion. Agonist and cell-type speciﬁc parameters
may be added by using the generated templates within the Virtual Cell
system (www.nrcam.uchc.edu). Alternatively, the system (including the
generated ordinary differential equations) can be exported to other
simulation programs by way of the export functions on the XML part of
the Virtual Cell model page. Thus, the simulation suite is designed to be
portable and available to a wide variety of researchers. All simulations
presented in this work used the Runge-Kutta fourth-order solver with a ﬁxed
time step of 0.1 ms. The Virtual Cell biomodel can be found in the public
directory Ca_release_coupled_MLC.
Prototype model for agonist-coupled
Ca21 signaling
The model design (Fig. 1) contains three compartments, plasma membrane,
cytosol, and ER. The volume ratio ER/cytosol is 0.15, typical of cultured
cells with a total cell volume of 13 1015 cm3 employed in most cell model
systems (Slepchenko et al., 2002; Fink et al., 1999; Lemon et al., 2003b;
Riccobene et al., 1999). The plasma membrane is the starting point for the
design of the system. It contains a G-protein-coupled receptor, PLC and
other lipid transforming enzymes. To simplify the overall system the plasma
membrane Ca21 channels and efﬂux pumps were not implemented so that
only IP3-generated Ca21 ﬂuxes arising from the ER compartment are used.
For systems where Ca21 and other ion channel(s) activated by agonists
are important, these features may be added as needed. However, the
simpliﬁcation offered in the current model is justiﬁed because other model
systems dealing with IP3-generating and Ca21-release modules have been
successful at explaining experimental data with this closed system (Lemon
et al., 2003a; Fink et al., 2000; Shea and Linderman, 1997).
Plasma membrane components:
G-protein-coupled receptor formulation
The formulation of agonist-mediated signaling through G-protein-coupled
receptors is based upon modern receptor theory (Kenakin and Onaran, 2002;
Kenakin, 1997, 2002) guided by existing treatments for receptors coupled to
heterotrimeric G-proteins containing the Gq subunit that activates phospho-
lipase C and downstream signaling. A generic GPCR receptor model
(Riccobene et al., 1999; Kenakin, 2002) is shown in Fig. 2. This model
includes the concept of receptor coupling G-protein and ligand in a
complementary fashion that enhances the response of the ligand (L) (Eq. 1)
(Kenakin, 2002):
Response ¼ e½L=ð½L1KdÞ: (1)
The enhancement obtained depends upon the concentration of G-protein
and its afﬁnity for the receptor in the presence and absence of ligand (Fig. 2).
In themodel, two receptor species (R* andR) representingG-protein-coupled
and uncoupled species interact with ligand (L). Receptors bound to the
G-GDP heterotrimeric complex (R*) are assumed to be in their high-afﬁnity
state (coupled receptors), whereas uncoupled (R) are lower afﬁnity. The cou-
pling factor, a, is applied to the forward rate constant (kf) for ligand bind-
ing to ‘‘coupled receptor.’’ Ligand also binds to uncoupled receptor that
then engages G-protein complex with a applied to Kact, the receptor acti-
vation constant. The ternary complex (receptor bound to both ligand and
G-protein) as a ratio (r) of total receptor is given by Eq. 2 (Kenakin and
Onaran, 2002):
r ¼ Kactð11a½L=KdÞ½L=Kdð11aKactÞ1Kact1 1: (2)
r ¼ að11KactÞ=ð11aKactÞ (2:1)
FIGURE 1 Three-compartment cell model containing plasma membrane,
cytoplasmic reticulum, and ER. The primary activities modeled using the
Virtual Cell are the GPCR-mediated activation of phospholipase C, Ca21
release and uptake in the ER, and activation of the CaM-MLCK complex.
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In the absence of ligand, Eq. 2 reduces to Eq. 2.1, where r represents the
fraction of precoupled receptors. Previous modeling of complexes for typical
GPCRs indicated that a range of 10–30% of the receptors may be precoupled
to G-protein (Shea and Linderman, 1997). In the current generic model, the
fraction of precoupled receptors was set within this range by the values of a
and Kact. In the ternary complex (LR*), G-protein exchanges GDP for GTP,
followed by G-protein complex dissociation. In the current simpliﬁed model,
constitutively active receptors are ignored as they are assumed to have low
intrinsic GTP exchange activity in line with experimental data (Shea and
Linderman, 1997). However, constitutively active GPCRmutants are known
(Parnot et al., 2002), so that these species can be activated if needed.
Desensitization of the activated receptor was modeled as an irreversible
phosphorylation (rate constant¼ kds) by a G-protein receptor kinase (GRK)
that inactivates further signaling (Kenakin, 1997; Woolf and Linderman,
2003). The decay of the activated Gq through GTP hydrolysis eventually
terminates the generated signal. Table 1 summarizes ligand binding and dose-
response information about speciﬁc Gq coupled receptors. A highly coupled
system (a . 10) will generate the maximal amount of activated Gq.
Inspection of the data on some GPCR receptors (Table 1) indicates that the
EC50 of Ca21 or downstream events is usually less than the Kd of the ligand
for the receptor, suggesting coupling of the signaling process. However, data
for some agonists, such as bradykinin B2 and Arg-vasopressin receptors is
different because the EC50s are greater than the Kd of the ligand. This does
not necessarily mean that there is no coupling, but suggests that a process
downstream of the ligand-receptor-G-protein complex is low efﬁciency. For
example, this could be due to the inactivation of G-protein signaling by the
activity of RGS proteins that bind activated G-proteins and catalyze GTP
hydrolysis (Zhong et al., 2003; Woolf and Linderman, 2003). The generic
model contains 20,000 receptors and 100,000 heterotrimeric G-proteins per
cell. The ligand-binding constant (Kd) is 0.01 mM, and the coupling factor
a ¼ 1000. Appendix A contains the formulations (Eqs. A1–A3) used in the
Virtual cell that describe receptor activation and generation of activated
G-protein, Gq-GTP.
Phosphatidyl-inositol synthesis
Fig. 3 illustrates the details of the phosphoinositide synthesis and generation
of the messengers diacylglycerol (DAG) and IP3 by phospholipase C. It has
been established that agonist-mediated Ca21 signaling involves more than
just the activation of phospholipase C, because pools of its substrates within
the plasma membrane are ﬁnite (Toker, 1998). Thus, for sustained agonist
stimulation and signaling, continuous synthesis of the PLC substrate
(phosphatidyl-4,5, bisphosphate, PIP2) and upstream precursors must occur
(Toker, 1998; Weernink et al., 2000; Rumenapp et al., 1998). Although the
enzymes that participate in PIP2 synthesis are known (Fig. 3), their regulatory
paradigm with regard to GPCRs is not clear. Experimental evidence
implicates Rho GTPases (Weernink et al., 2000; Rumenapp et al., 1998;
Schmidt et al., 1996) and activation by selected lipid products (Moritz et al.,
1992) as participants in modulating PIP2 levels. Previous modeling efforts in
this regard employed a resynthesis factor coupled to IP3 production to
replenish PIP2 consumed by PLC (Lemon et al., 2003b), stimulated and basal
synthesis factors (Xu et al., 2003), and a feedback network based upon
synthesis of other inositol phosphates downstream of IP3 (Mishra and Bhalla,
2002). Among these options, an existing Virtual Cell model (Xu et al., 2003)
provided a reasonable approach to this problem. First, a basal synthesis term
(Vbasal) is activated if PIP2 falls below a preset level. This strategy allows
replenishment of PIP2 after agonist stimulation, typically within a few
minutes. The second term is a stimulation of PIP2 synthesis (Vstim) during the
peak of PIP2 consumption by PLC. This allows a bolus of PIP2 to become
available during the peak of IP3 synthesis and prevents complete depletion of
the PIP2 supply. These termswere combined as and expressed as exponentials
as shown in Eqs. A4 and A5–A6 (Appendix).
Phospholipase C activation
PLC is expressed as several isoforms that exhibit differential sensitivity to
Gq and bg G-protein subunits as well as Rho GTPases (Rhee and Bae,
1997). The PLCb1 and PLCbB2 isoforms are the primary transducers of
Gq-mediated signals in the central nervous system and smooth muscle cells,
whereas PLCb3 transduces bg signals and is found in myeloid cells
(Illenberger et al., 2003). Formulation of PLC activity was based upon the
kinetic parameters found with reconstituted PLCb1 (Mukhopadhyay and
Ross, 1999; Smrcka et al., 1991). Two convergent paths were used to
generate full PLC activity (Fig. 4). These involved the sequential activation
TABLE 1 Ligand binding and dose/response data for some Ca21 mobilizing GPCRs
Receptor Ligand Kd (nM)
EC50 (nM)
Ca21 response or activity (–) References
Generic 10 3 See Text
Bradykinin B1 7000 300 (Leeb-Lundberg et al., 2001)
Bradykinin B2 0.3 2 (Marsh and Hill, 1993; Schaeffer et al., 2001)
Chemokine pep1 4.4 0.4– (Riccobene et al., 1999; Adams et al., 1998)
Chemokine pep2 60 60– (Riccobene et al., 1999; Adams et al., 1998)
Purine-P2Y2(UTP) 5000 250 (Garrad et al., 1998)
Endothelin 0.5–70 (Muldoon et al., 1989; Takuwa et al., 1990)
Arg Vasopressin 0.5 1–19 (Monck et al., 1988; Moneer and Taylor, 2002)
FIGURE 2 Generic GPCR receptor model details. The model is based
upon the precoupled receptor concept (Shea and Linderman, 1997)
including high-afﬁnity coupled (R*) and low-afﬁnity uncoupled (R)
receptors for ligand (L) binding.
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of PLC by Gq-GTP and Ca21 to generate the active enzyme Ca21-PLC–Gq-
GTP. Under resting conditions, PLC is distributed between native and Ca21-
bound forms as established by the equilibrium constant Kc-plc-b (;1
mM)(Smrcka et al., 1991). As Gq-GTP is generated, both forms proceed to
form the active complex. However, because of thermodynamic coupling,
Ca21 binds to PLCb-Gq with higher afﬁnity than PLCb alone (Kc-plc-s ¼
0.1 mM) (Smrcka et al., 1991). Similarly, the rate constant for the Gq-GTP
activation of Ca21-PLCb is 10-fold higher than the apoenzyme (Table 2).
PLC enzymatic activity is down-regulated through GTP hydrolysis within
the complex. The rate of this GTPase activity (6/s) is signiﬁcantly faster than
the basal GTPase activity of Gq (0.15/s) due to the GAP (G-protein
activating protein) activity of PLC (Mukhopadhyay and Ross, 1999). Thus,
it is assumed that the activated complex Ca21-PLCb-Gq-GTP is responsible
for most of the stimulated PLC activity. Because Ca21-PLCb has
a somewhat lower speciﬁc activity than the Gq-activated form (Smrcka
et al., 1991), this species is a minor contributor to PLC activity and in the
current model formulation provides the basal activity. Eqs. A7 and A8 (see
Appendix) describe the PIP2 hydrolysis steps carried out by PLCb
providing stimulated and basal levels of IP3. The kinetic parameters used
for these processes are summarized in Table 2.
ER compartment
The intracellular Ca21 compartment (ER) contains the IP3 release channel,
and the ER Ca21 pump (SERCA). There are several mathematical models
(Schuster et al., 2002; Goldbeter et al., 1990; Li and Rinzel, 1994) for
dealing with IP3-generated intracellular Ca21 ﬂuxes. Some of these models
allow for oscillations in Ca21, whereas others do not. The model used for
a smooth muscle prototype is nonoscillatory under normal IP3 and Ca21 ﬂux
conditions (Fink et al., 1999). The IP3-mediated Ca21 release and SERCA
activities are derived from minimal variable formulations (Li and Rinzel,
1994; Keizer and De Young, 1994) as implemented by Loew and co-
workers in the Virtual Cell (Fink et al., 1999, 2000).
Cytoplasmic compartment
Ca2, CaM-complexes, and the activation of MLCK
The participating elements in theMLCKmodule are illustrated in Fig. 5. The
active Ca21-CaM-MLCK complex is generated from two paths similar to
PLCb (Fig. 3). In the ﬁrst, preformed complexes of CaM and MLCK bind
Ca21 and are activated. In the second path, the Ca21-CaM complex binds to
MLCK forming the same active complex. Estimates of the afﬁnity of CaM
and MLCK in the absence of, or low, Ca21 conditions vary widely. Peptide
analogs of the CaM binding domain of MLCK interact with CaM in the
absence of Ca21 with an ionic strength-dependent Kd of 5–270 mM. CaM-
MLCK complexes have also been detected at very low Ca21 (Wilson et al.,
2002; Milos et al., 1988). Thus, preformed CaM-MLCK complexes were
included in the formulation of MLCK activation. The CaM-MLCK
equilibrium constant was set at 27 mM, as a lower limit assuming that the
ionic strength within the cytoskeletal environment is favorable for complex
formation. Using this value, 0.36 mM CaM-MLCK complex is formed at
equilibrium with 1 mM CaM and 10 mM MLCK (Taylor and Stull, 1988).
This amount of CaM-MLCK complex represents;11% of the CaM retained
in cytoskeletal cell fractions (Wilson et al., 2002). Ca21 binding to CaM in
the presence and absence of target proteins was formulated as mass action
equilibria (Eq. 3), with an exponent, n, on the Ca21 corresponding to the Hill
coefﬁcient for binding derived from modiﬁed Adair-Klotz equations that
account for coupling between target binding and Ca21 to CaM (Haiech et al.,
1991; Mirzoeva et al., 1999):
Ca
21
binding rate ¼ kfCa½CaM½Ca21n
 krCa½Ca21-CaM: (3)
CaM-MLCK complexes were formulated similarly, except that CaM in
Eq. 3 is replaced by CaM-MLCK. The on/off rates for Ca21 to CaM in the
presence and absence of MLCK were adjusted based upon in vitro
measurements found in the literature (Johnson et al., 1996; Black et al.,
2000). Similarly, on/off rates for Ca21-CaM binding to MLCK were based
upon available in vitro data (Johnson et al., 1996; Kasturi et al., 1993).
Because the off-rate of Ca21 from CaM and CaM-target complexes is
biphasic (Kasturi et al., 1993), an average value was used. Relevant
parameters used in the simulation are in Table 3. Simulations were begun
with equilibrium values for CaM-MLCK, CaM-buffer protein, and Ca21-
CaM-MLCK complex obtained by running simulations for several minutes
without IP3 generation. Myosin light chain concentration was set at 24 mM.
A modiﬁed Michaelis-Menton equation (Eq. 4) with explicit enzyme
concentration (Mendes, 1997) was used for MLCK activity based upon the
level of Ca21-CaM-MLCK complex:
Rate ¼ Kcat½enzyme½substrate=ðKm1 ½substrateÞ: (4)
FIGURE 3 Phospholipid synthesis cascade. In the model, the phospha-
tidylinositol (PI) and phosphatidyl 4-phosphate (PIP) are ﬁxed. The PLC
substrate, phosphatidylinositol 4,5-bisphosphate (PIP2) is synthesized at
a combined basal and stimulated rate from PIP. (See Eqs. 6–7).
FIGURE 4 Activation of PLC by dual pathways. The Ga subunit Gq-GTP
interacts with PLC to form active complex PLCb-Gq-GTP that has high
afﬁnity for Ca21 thus creating the active enzyme Ca21-PLCb-Gq-GTP that
hydrolyzes PIP2 to DAG and IP3 (Fig. 3). Ca21-PLCb provides the basal
activity in the absence of activated Gq proteins.
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MLCP and regulatory elements
The myosin light chain phosphatase kinetic parameters were based upon in
vitro measurements of the phosphorylated and nonphosphorylated enzyme
where the phosphorylated form has a fraction (0.07–.2) of the speciﬁc
activity of the unphosphorylated species (Table 3). More details on the
regulation of MLCP by phosphorylation and inhibitory proteins is in the
companion article (Lukas, 2004). These include phosphorylation of
the regulatory subunit (MYPT), activation of the phosphatase inhibitor
(CPI-17), and cyclicGMP-mediated inhibition of MYPT phosphorylation.
RESULTS
Generic model
In a typical simulation using the generic model, binding of
ligand to GPCR increases the level of active Ca21-CaM-
MLCK complex after the rise in IP3 and Ca21(Fig. 6 A). A
ligand (Kd ¼ 10 nM) at a concentration of 100 nM causes
a Ca21 ﬂux that peaks at 0.71mM, comparable to the range of
0.25–0.85 mM measured in smooth muscle cells (Simpson
and Ashley, 1989; Taylor and Stull, 1988; Willars et al.,
1998). The ultimate Ca21 peak also depends upon the level of
Ca21 buffering. In this smooth muscle cell model, a single
buffer was used at a concentration of 350 mM and a Kd of
10 mM (Fink et al., 1999). Reducing the Ca21 buffer
concentration fourfold to 87.5 mM increases the peak Ca21
to 1mM. Thus, the peak Ca21 is relatively insensitive to Ca21
buffer concentration within the range tested. Activated CaM-
MLCK complex peaks at ;2 mM, or ;20% of the total
MLCK. The Ca21 output is also limited by the IP3 production
that maximizes at 1.1 mM. The IP3 receptor Ca21 release
parameters for smooth muscle cells (Fink et al., 1999) make
the channel more sensitive to IP3 than in neuronal cell models
(Fink et al., 2000). The ligand dependence of peak Ca21 in the
model simulations is shown in Fig. 6 B. The proﬁle parallels
that observed for bradykinin stimulated smooth muscle cells
(Fig. 6 B, inset). In an expanded view of the IP3 and Ca21
release (Fig. 7), the proﬁles are biphasic. This result was
expected because the initial fast phase of Ca21 release follows
the peak of IP3 synthesis when the PIP2 supply is maximal,
whereas the second phase (not a plateau) reﬂects sustained
release at a lower IP3 synthesis rate as PIP2 resynthesis occurs
(Fig. 7 B). Compared to data from Arg-vasopressin treated
vascular smooth muscle cells in the absence of extracellular
Ca21 (Simpson and Ashley, 1989) (Fig. 7 A), the simulation
data exhibit a faster rise in Ca21, but the second phase and
decay are similar. In a study of smooth muscle cells treated
with the Ca21 mobilizing agonist, carbachol (Willars et al.,
1998), the stimulated IP3 production and Ca21 levels
exhibited a rapid peak followed by a second slower phase
that was eliminated when cells were pretreated with
wortmannin, an agent that inhibits PI-4 kinase in the PIP2
synthetic pathway (Fig. 3). Therefore, the Gq-GTP-activated
PLC, IP3 generation, PIP2 replenishment, and Ca21 release
parameters used in the simulation adequately describe these
processes in living cells. The use of precoupled receptors (see
above) may be partly responsible for the faster rise in IP3 and
Ca21 in the simulation results because without precoupling,
the Ca21 peak shifts to the right (Fig. 7 A). Thus, the delay in
Ca21 generation observed experimentally may be due to
differences in receptor precoupling and/or receptor number
TABLE 2 Phospholipase C IP3/DAG parameters
Reaction Kd mM kf 106 M1 s1 kr s1
PLC 1 Gq-GTP/ PLC-Gq-GTP 0.0042 1
PLC 1 Ca4 Ca21-PLC 1.0
PLC-Gq-GTP 1 Ca214 Ca21-PLC-Gq-GTP 0.1
Ca21-PLC 1 Gq-GTP/ Ca21-PLC-Gq-GTP 0.042 1
PIP2 1 Ca21-PLC-Gq*/ DAG 1 IP3 Kcat ¼ 50/s
PIP2 1 Ca21-PLC/ DAG 1 IP3 (basal) 0.0002 1
Ca21-PLC-Gq*/ Ca21-PLC 1 Gq 6 /s
IP3-deg 1.25/s
DAG-deg 0.15/s
Parameters are based on work by Sivakumaran et al. (2003) and Smrcka et al. (1991).
FIGURE 5 Ca21-calmodulin-associated signaling elements. Shown are
the details of the MLC phosphorylation/dephosphorylation module. The
model and simulation system contain dynamic regulation of MLCK and
MLCP activities through second messenger-mediated phosphorylation/
dephosphorylation events. The effectors are shown in boxes and second
messengers in circles.
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per cell (compared to the generic model). Thus, to achieve
a closer correspondence between simulation predictions and
experimental data, the simulation parameters must be op-
timized for a speciﬁc agonist and cellular background (see
below).
To investigate the dynamic range of the generic model, the
time course of MLC phosphorylation was simulated for
ligand concentrations of 3–300 nM, assuming aKd of 10 nM).
Fig. 8 illustrates the results obtained from such a simulation.
As the ligand concentration increases, both the peak
concentration of phosphorylated MLC and the time frame
are affected. The lowest ligand concentration exhibits a peak
at 15 s,whereas the higher ligand concentrations peak at 4–8 s.
These differences are a result of the timing of multiple
phosphorylation events (on the regulatory subunit of MLCP
or the inhibitory protein CPI-17) that either precede or are
coincident with MLC phosphorylation. How these events
affect the overall response of the system is further investigated
in the accompanying article (Lukas, 2004).
Modeling of bradykinin receptors
Using the generic GPCR model as a template, the model was
applied to Ca21-mobilizing bradykinin receptors to test the
simulation system. The bradykinin B2 receptor is a high-
afﬁnity species that is widely distributed, whereas the B1
receptor is lower in afﬁnity and abundance in most smooth
muscle tissues, but may be up-regulated during inﬂammatory
conditions (Leeb-Lundberg et al., 2001). How the Kd of the
receptor changes the response of the simulation system is
shown in Fig. 9. In these simulations, the bradykinin B2
receptor (Kd ¼ 0.3 nM) is compared to the bradykinin B1
receptor (Kd ¼ 7 mM) over a ligand concentration range of
0.01–10 mM. The predicted EC50 (peak Ca21 response) for
the B2 receptor is 2.2 nM (Fig. 9 A), whereas the B1 receptor
is 0.78 mM (Fig. 9 B) (compare to Table 1: 2 nM and 0.3
mM, respectively). Thus, the low-afﬁnity B1 receptor is not
accurately modeled with the current system parameters such
as the receptor G-protein coupling or the ligand binding on-
rate. Because the binding kinetics for B1 receptors varies
with ligand (Leeb-Lundberg et al., 2001; Schaeffer et al.,
2001), the EC50 for Ca21 mobilization may be due to
a difference in receptor binding kinetics. A ﬁvefold
enhancement of ligand on-rate was applied to both the pre-
coupled receptor R* and the uncoupled receptor R (Fig. 2).
Now the predicted Ca21 and active CaM-MLCK complex
formation from ligand binding at the B1 receptor has li-
gand dependence as shown in Fig. 9 C and exhibits an EC50
of 0.24 mM (peak Ca21 response), more consistent with
experiment. Another important difference between the
bradykinin receptors is that the B1 receptor is not down-
regulated through a phosphorylation mechanism (Leeb-
Lundberg et al., 2001) so that its desensitization is slower
than the B2 receptor. To determine the characteristics of a cell
containing both receptors, a hypothetical cell was created
with them in the system.
In the two-receptor system, equal numbers of B1 and B2
receptors were used. The B1 receptors were all precoupled,
and decay of the activated receptor was through dissociation
of Gq-GTP. There was no desensitization through receptor
phosphorylation. The Ca21 release and MLC phosphoryla-
tion proﬁles exhibit an elevated baseline after the peak at
high ligand concentrations (Fig. 10). Although the bradyki-
nin concentration required for this effect is nonphysiological
(30 mM), the B1 receptor is selectively activated by desArg-
9-bradykinin at nanomolar concentrations (Marsh and Hill,
1994), and may also exhibit constitutive activation (Leeb-
Lundberg et al., 2001). Therefore, the simulation data predict
that expression of the B1 receptor will change the baseline
levels of MLC phosphorylation and Ca21 within smooth
muscle cells in the presence of selected agonists or con-
stitutive activation.
DISCUSSION
Through computer simulation it is possible to model a
complete Ca21 signaling process beginning with a plasma
membrane receptor and ending with a protein phosphoryla-
tion event such as myosin light chain phosphorylation. The
model, as implemented in the Virtual Cell, provides multiple
modules that consider multiple protein phosphorylation/
TABLE 3 Ca21, CaM, MLCK, PKC, and MLCP parameters
Reaction Kd (mM)
kf (on-rate)
M1 s1 References
MLCK 1 CaM4 CaM-MLCK 27 5 (Tsvetkov et al., 1999), see text
4Ca21 1 CaM-MLCK4 Ca21-CaM-MLCK 0.5* 7.5* (Tansey et al., 1994; Johnson et al., 1996; Sivakumaran et al., 2003)
CaM 1 4Ca214 Ca21-CaM 2.5 12* (Davis et al., 1999; Johnson et al., 1996; Black et al., 2000)
Ca21-CaM 1 MLCK4 Ca21-CaM-MLCK 0.0011 28 (Johnson et al., 1996; Kasturi et al., 1993)
Ca21-CaM 1 MLCK-P4 Ca21-CaM-MLCK-P 0.023 8 (Johnson et al., 1996; Kasturi et al., 1993)
Enzyme kinetics Km mM Kcat s1
Ca21-CaM-MLCK 1 MLC/ MLC-P 10 27 (Ikebe and Reardon, 1990)
MLCP 1 MLC-P/ MLC 15 16 (Feng et al., 1999; Ichikawa et al., 1996)
MLCP-P 1 MLC-P/ MLC 58 2.1 (Feng et al., 1999; Ichikawa et al., 1996)
*Values were optimized by comparison to experimental data.
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dephosphorylation events initiated by the engagement of a G-
protein-coupled receptor and ligand. Thus, simulations based
upon the model provide a means to predict the course of these
events that at deﬁned time points can be monitored (post-
reaction) using phosphorylation site-selective reagents (anti-
bodies, phosphomotif binding proteins, etc.). Multiplex
assays for analyzing the activation of selected kinases are
now available (Hu et al., 2003), and real-time measurements
of a few protein kinase activities are being developed (Wu
et al., 2001). Thus, the Ca21 signaling model presented here
provides a tool for evaluating these types of data, and how
changes in signaling systems will affect the measured
endpoints. Now, instead of just forecasting the initial
messenger production (Ca21, cyclicAMP, IP3, etc.), the
signaling prototype presented here provides for coupling
these messengers to multiple downstream processes simulta-
neously. Thus, the time course is extended to all relevant
signaling events, such as kinase cascades, other second
messengers, and endpoints that were not yet connected to
Ca21 signals. Although much work remains to be done to
extend the created models to other cell types and systems, the
prototype developed here serves as an extensible tool for this
task.
For example, the initiating process, ligand binding to
a GPCR, was formulated as a multistate collision model
previously established by Linderman (Shea and Linderman,
1997). Ligand binding and receptor number data are
available for several Gq-coupled receptors in native cultured
cells or transfected cell lines (Nakamura et al., 1995),
allowing the prediction of Ca21 ﬂuxes, IP3, and DAG
generation (second messengers), and downstream endpoints.
FIGURE 6 Simulation results of a time course of ligand-GPCR-activated
processes. (A) Shown are curves for the stimulation of cells with 100 nM
agonist (103 Kd) yielding Ca21-CaM-MLCK complex formation (solid
line), Ca21 release (dotted line), and IP3 (dot-dash line). (B) Prediction of
the ligand dependence of the peak of IP3 (squares), Ca21 (triangles), and
Ca21-CaM-MLCK complex (circles) through activation of the receptor-
linked downstream processes. Inset has an experimental example of the
dependence of Ca21 peak on bradykinin concentration in stimulation of
smooth muscle cells (adapted from Marsh and Hill, 1993).
FIGURE 7 Comparison of the predicted Ca21 response with experimental
results. (A) Output from simulations of the model GPCR-coupled receptor
with 100 nM agonist (103 Kd) . IP3 (dashed line)-induced Ca21 release
(dotted line) in the model containing precoupled receptors is faster than
that from the model without receptor precoupling (dot-dash line). The
experimental data (solid line with points) is the Ca21 response from smooth
muscle cells stimulated with Arg-vasopressin (adapted from Simpson and
Ashley, 1989). (B) Proﬁle of IP3 generation (dashed line), PIP2 (dotted line),
and activated PLC (solid line) from the precoupled receptor model initiated
with 100 nM agonist. The peak of IP3 response corresponds to the peak of
PLC activity and the consumption of PIP2.
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The novel aspect of the current work is the coupling of the
second messengers (Ca21/DAG) to their upstream (IP3/Gq)
and downstream effectors. For cytoplasmic Ca21, the
primary effector is calmodulin and its target molecules,
whereas with DAG, the primary signaling is through PKC.
Modeling these processes required knowledge of binding
parameters, kinetics, and estimates of the cellular concen-
trations of the key species. In cases where in vitro
experimental data are available (Table 1), they are adequate
for parameterization. Most of the uncertainty in the levels
of lipids, phosphatases, and other species in the model are
cell type-speciﬁc and may be scaled as needed without
dramatically changing the qualtity of endpoint predictions.
For the simulation of the Ca21 signaling process to be able
to mimic cellular events, the signal control elements must be
included. These include: phosphatase activities that counter
activated kinases, degradation or resequestration of second
messengers, and consideration of other cellular cross-talk that
may inﬂuence the measured cellular endpoints. In the case
of MLCK, phosphorylation at sites in the CaM-regulatory
domain by CaMKII and PAK-1 decrease the Ca21-CaM
sensitivity of the kinase; thus, assessment of MLCK
phosphorylation state in vivo at these sites is the next step
needed to reﬁne the current model. In the companion article
(Lukas, 2004), the role of phosphorylation of MLCK and
several of the controlling elements for myosin phosphatase
activity are expanded in the context of the model. For
example, in the regulation of phosphatase activity both
phosphorylation of the regulatory subunit and activation of
the inhibitor protein CPI-17 are included.
The model and simulation environment developed in this
work are applicable to a variety of Ca21-mobilizing GPCRs.
FIGURE 8 Effects of GPCR ligand/agonist concentration on the proﬁle of
MLC phosphorylation predictions. Using the generic model with receptor
precoupling, the agonist concentration was varied (3–300 nM). The MLC
phosphorylation proﬁle is shown with the thickest line corresponding to
3 nM, and lines of decreasing thickness represent 10, 30, 100, and 300 nM
respectively. The greatest shift in peak time occurs between the application
of 3 and 30 nM agonist.
FIGURE 9 Predicted Ca21-CaM-MLCK complex formation (circles) and
peak Ca21 concentration (boxes) for different bradykinin receptors. (A)
Simulated dose-response curves for the high-afﬁnity B2 receptor using the
published parameters (Table 1). (B) Simulated dose-response curves for the
low-afﬁnity B1 receptor with no change in receptor kinetics. (C) Simulated
dose-response curves for the B1 receptor with a ﬁvefold increase in the on-
rate parameter.
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Speciﬁc demonstration of predicted responses with the B1
and B2 bradykinin receptors indicates that receptor-speciﬁc
parameters such as ligand-binding kinetics, mode of desen-
sitization, and receptor number are needed tomodel additional
receptor species. These data may be obtained experimentally
using heterologous expression in cultured cells (Leeb-
Lundberg et al., 2001), or through pharmacologic manip-
ulation of native receptors (Marsh and Hill, 1993, 1994;
Schaeffer et al., 2001).
CONCLUSIONS
Using the Virtual Cell environment, the current modeling
effort provides a facile tool for biochemists and other life
scientists to describe Ca21 signal transduction processes
in quantitative terms. The logical extension of the model
presented here is the addition of other GPCRs that couple to
other effectors such as adenylate cyclase, ion channels, etc.
This will allow more robust experimental design as the
simulations can be used to predict quantitative biological
endpoints. Incorporation of new modules that dynamically
regulate cGMP levels, RhoA and activation of other G-pro-
teins will produce a simulation environment that couples
multiple signaling pathways to convergent processes. Such
efforts are currently in progress.
APPENDIX
The rate of formation of activated ligand-receptor-G-protein complex, LRG,
is given by Eq. A1:
d½LRG=dt ¼ a3 kf 3 ½L½RG  kf3Kd3 ½LRG
1 kf 3Kd3 ½LR½G; (A1)
where Kd is the ligand binding constant, kf is the forward rate constant, and
a is the coupling factor. In the generic model, Kd¼0.01 mM, a¼ 1000, and
kf ¼ 10 3 106 M1 s1. This is an average on-rate based upon values
derived for chemokine receptors (Shea and Linderman, 1997). The rate of
binding of uncoupled receptors to ligand is obtained from Eq. A2:
d½LR=dt ¼ kf3 ½L3 ½R  kf3Kd3 ½LR: (A2)
Similarly, the rate of formation of precoupled receptors, RG, is obtained
from Eq. A3:
d½RG=dt ¼ kfG3 ½R½G  Kact3 kfG3 ½RG; (A3)
where Kact is the equilibrium constant for receptor precoupling and kfG is
the forward rate constant. In the generic model, kfG was set to diffusion-
limited (108 M1 s1) and Kact adjusted to obtain the desired level (25%) of
precoupled receptors.
Modeling of phospholipid synthesis was accomplished using Eqs. A4–
A6 to describe stimulated and basal PIP2 synthesis:
PIP2 synthesis ¼ ðVstim1VbasalÞ3 ½PIP (A4)
Vstim ¼ Kstim3 ðeðt-tauÞ=stimdecayÞtau ¼ 0:2 s (A5)
Vbasal ¼ Kbasal3 ð11 eðPIP2basalPIP2Þ=PIP2basalÞÞ: (A6)
Phospholipase C activation was formulated using the constants in Table 2
and Eqs. A7–A8:
d½PLCact=dt ¼ kfp3 ½PLC3 ½Gq-GTP
1 kfp#3 ½Gq-GTP½Ca21-PLC
 kr3 ½PLCact (A7)
d½Ca21-PLC=dt¼ kfca3 ½PLC3 ½Ca21
 kfca3Kc-plc-b3 ½Ca21-PLC: (A8)
Synthesis of IP3 and DAG was formulated using Eq. 10 and constants in
Table 2:
d½IP3=dt ¼ Kcat3 ½PIP23 ½PLC act3 ð½Ca21=
ðKc-plc-s1 ½Ca21Þ (A9)
The Virtual Cell Portal is provided by the National Resource for Cell
Analysis and Modeling supported by National Institutes of Health grant
5P41RR013186.
FIGURE 10 Predicted Ca21 and myosin light chain phosphorylation
proﬁles for a cell containing equal numbers of bradykinin B1 and B2
receptors. (A) Predicted Ca21 response by application of 3 mM (dotted line)
and 30 mM (solid line) of bradykinin. (B) Predicted MLC phosphorylation
proﬁle as a function of time with the same treatments. Note the elevated
baseline (particularly at 30 mM) after the peak of Ca21 or MLC phos-
phorylation.
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